logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Jul 9, 2015

PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agent

  • Jun 30, 2015

PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel

  • Jun 29, 2015

PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel

  • Jun 23, 2015

PharmaCyte Biotech Enters Into Research and Consulting Agreements With University of Technology Sydney

  • Jun 18, 2015

PharmaCyte Biotech's Dr. Mark Rabe Discusses the Significance of Schedule 1 License to Company's Future in Cannabis Research

  • Jun 16, 2015

PharmaCyte Biotech Showcasing Technology and Treatments at 2015 BIO International Convention

  • Jun 15, 2015

PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License

  • Jun 12, 2015

PharmaCyte Biotech’s Diabetes Treatment to Be Presented at Austrodrugs 2015

  • Jun 10, 2015

PharmaCyte Biotech Officers to Attend 2015 BIO International Convention

  • Jun 9, 2015

PharmaCyte Biotech’s Contract Research Organization Voted Australia’s Favorite CRO for 2015

RSS
  • « Previous
  • 1...
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease May 21, 2024
  • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023